Agmatine: Identification and inhibition of methamphetamine, kappa opioid, and cannabinoid withdrawal in planarians

Synapse

Volumn 62, Issue 12, 2008, Pages 927-934

  Rawls, Scott M ^a   Gerber, Kristin ^a   Ding, She ^a   Roth, Christopher ^a   Raffa, Robert B ^a  

^a TEMPLE UNIVERSITY SCHOOL OF PHARMACY   (United States)

Author keywords

Agmatine; Cannabinoid; Dependence; Kappa opioid; Methamphetamine; Planaria

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE; AGMATINE; ARGININE; METHAMPHETAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR; CONTROLLED STUDY; DRUG EFFECT; DRUG EXPOSURE; DRY WEIGHT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INHIBITION KINETICS; LOCOMOTION; NEUROCHEMISTRY; NONHUMAN; PRIORITY JOURNAL; TURBELLARIA; WITHDRAWAL SYNDROME;

3,4-DICHLORO-N-METHYL-N-(2-(1-PYRROLIDINYL)-CYCLOHEXYL)-BENZENEACETAMIDE, (TRANS)-ISOMER; AGMATINE; ANIMALS; BENZOXAZINES; CANNABINOIDS; METHAMPHETAMINE; MORPHOLINES; MOTOR ACTIVITY; NAPHTHALENES; PLANARIANS; RECEPTORS, OPIOID, KAPPA; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 56549104400     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.20571     Document Type: Article

References (68)

1. Algeri S, Carolei A, Ferretti P, Gallone C, Palladini G, Venturini G. 1983. Effects of dopaminergic agents on monoamine levels and motor behaviour in planaria. Comp Biochem Physiol C 74:27-29.
2. Aricioglu-Kartal F, Uzbay IT. 1997. Inhibitory effect of agmatine on naloxone-precipitated abstinence syndrome. Life Sci 61:1775-1881.
3. Aricioglu F, Paul IA, Regunathan S. 2004a. Agmatine reduces only peripheral-related behavioral signs, not the central signs, of morphine withdrawal in nNOS deficient transgenic mice. Neurosci Lett 354:153-157.
4. Aricioglu F, Means A, Regunathan S. 2004b. Effect of agmatine on the development of morphine dependence in rats: Potential role of cAMP system. Eur J Pharmacol 504:191-197.
5. Cebria F, Kudome T, Nakazawa M, Mineta K, Ikeo K, Gojobori T, Agata K. 2002. The expression of neural-specific genes reveals the structural and molecular complexity of the planarian central nervous system. Mech Dev 116:199-204.
6. Cox D, Bowers R, McBride A. 2004. Reboxetine may be helpful in the treatment of amphetamine withdrawal. Br J Clin Pharmacol 58:100-101.
7. Creese I, Iversen SD. 1975. The pharmacological and anatomical substrates of the amphetamine response in the rat. Brain Res 83:419-436.
8. Eriksson KS, Panula P. 1994. γ-Aminobutyric acid in the nervous system of a planarian. J Comp Neurol 345:528-536.
9. Feng Y, Halaris AE, Piletz JE. 1997. Determination of agmatine in brain and plasma using high-performance liquid chromatography with fluorescence detection. J Chromatogr 691:277-286.
10. Galea E, Regunathan S, Eliopoulos V, Feinstein DL, Reis DJ. 1996. Inhibition of mammalian nitric oxide synthases by agmatine, an endogenous polyamine formed by decarboxylation of arginine. Biochem J 316 (Part 1): 247-249.
11. Gmerek DE, Woods JH. 1986. κ-Receptor mediated opioid dependence in rhesus monkeys. Life Sci 39:987-992.
12. Gmerek DE, Dykstra LA, Woods JH. 1987. κ-Opioids in rhesus monkeys. III. Dependence associated with chronic administration. J Pharmacol Exp Ther 242:428-436.
13. Kalra SP, Pearson E, Sahu A, Kalra PS. 1995. Agmatine, a novel hypothalamic amine, stimulates pituitary luteinizing hormone release in vivo and hypothalamic luteinizing hormone-releasing hormone release in vitro. Neurosci Lett 194:165-168.
14. Kimmel HD, Garrigan HA. 1973. Resistance to extinction in planaria. J Exp Psychol 101:343-347.
15. Kolesnikov Y, Jain S, Pasternak GW. 1996. Modulation of opioid analgesia by agmatine. Eur J Pharmacol 296:17-22.
16. Kusayama T, Watanabe S. 2000. Reinforcing effects of methamphetamine in planarians. Neuroreport 11:2511-2513.
17. Kuzirian A, Meyhöfer E, Hill L, Neary JT, Alkon DL. 1986. Autoradiographic measurement of tritiated agmatine as an indicator of physiologic activity in hermissenda visual and vestibular neurons. J Neurocytol 15:629-643.
18. Lago JA, Kosten TR. 1994. Stimulant withdrawal. Addiction 89:1477-1481.
19. Li G, Regunathan S, Barrow CJ, Eshraghi J, Cooper R, Reis DJ. 1994. Agmatine: An endogenous clonidine-displacing substance in the brain. Science 263:966-969.
20. Li J, Li X, Pei G, Qin BY. 1999. Effects of agmatine on tolerance to and substance dependence on morphine in mice. Acta Pharmacol Sin 20:232-238.
21. Loring RH. 1990. Agmatine acts as an antagonist of neuronal nicotinic receptors. Br J Pharmacol 99:207-211.
22. McGinty JF, Shi XD, Schwendt M, Saylor A, Toda S. 2008. Regulation of psychostimulant-induced signaling and gene expression in the striatum. J Neurochem 104:1440-1449.
23. McGregor C, Srisurapanont M, Jittiwutikarn J, Laobhripatr S, Wongtan T, White JM. 2005. The nature, time course and severity of methamphetamine withdrawal. Addiction 100:1320-1329.
24. Milanés MV, Laorden ML. 1998. Effects of U-50,488H withdrawal on catecholaminergic neurones of the rat ventricle. Br J Pharmacol 124:1060-1064.
25. Needleman HL. 1967. Tolerance and dependence in the planarian after continuous exposure to morphine. Nature 215:784-785.
26. Ness DK, Foley GL, Villar D, Hansen LG. 1996. Effects of 3-iodo-L-tyrosine, a tyrosine hydroxylase inhibitor, on eye pigmentation and biogenic amines in the planarian, Dugesia dorotocephala. Fundam Appl Toxicol 30:153-161.
27. Newmark PA, Sanchez Alvarado A. 2002. Not your father's planarian: A classic model enters the era of functional genomics. Nat Rev Genet 3:210-219.
28. Nguyen HO, Goracke-Postle CJ, Kaminski LL, Overland AC, Morgan AD, Fairbanks CA. 2003. Neuropharmacokinetic and dynamic studies of agmatine (decarboxylated arginine). Ann N Y Acad Sci 1009:82-105.
29. O'Brien CP, Greenstein R, Ternes J, Woody GE. 1978. Clinical pharmacology of narcotic antagonists. Ann N Y Acad Sci 311:232-240.
30. Onal A, Delen Y, Ulker S, Soykan N. 2003. Agmatine attenuates neuropathic pain in rats: Possible mediation of nitric oxide and noradrenergic activity in the brainstem and cerebellum. Life Sci 73:413-428.
31. O'shea TJ, Weber PL, Bammel BP, Lunte CE, Lunte SM, Smyth MR. 1992. Monitoring excitatory amino acid release in vivo by microdialysis with capillary electrophoresis-electrochemistry. J Chromatogr 608:189-195.
32. Palladini G, Ruggeri S, Stocchi F, De Pandis MF, Venturini G, Margotta V. 1996. A pharmacological study of cocaine activity in planaria. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol 115:41-45.
33. Passarelli F, Merante A, Pontieri FE, Margotta V, Venturini G, Palladini G. 1999. Opioid-dopamine interaction in planaria: A behavioral study. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol 124:51-55.
34. Piletz JE;Chikkala DN;Ernsberger P. 1995. Comparison of the properties of agmatine and endogenous clonidine-displacing substance at imidazoline and α-2 adrenergic receptors. J Pharmacol Exp Ther 272:581-587.
35. Raasch W, Regunathan S, Li G, Reis DJ. 1995. Agmatine, the bacterial amine, is widely distributed in mammalian tissues. Life Sci 56:2319-2330.
36. Raffa RB, Valdez JM. 2001. Cocaine withdrawal in planaria. Eur J Pharmacol 430:143-145.
37. Raffa RB, Desai P. 2005. Description and quantification of cocaine withdrawal signs in planaria. Brain Res 1032:200-202.
38. Raffa RB, Martley AF. 2005. Amphetamine-induced increase in planarian locomotor activity and block by UV light. Brain Res 1031:138-140.
39. Raffa RB, Valdez JM, Holland LJ, Schulingkamp RJ. 2000. Energy-dependent UV light-induced disruption of (-)sulpiride antagonism of dopamine. Eur J Pharmacol 406:R11-R12.
40. Raffa RB, Holland LJ, Schulingkamp RJ. 2001. Quantitative assessment of dopamine D2 antagonist activity using invertebrate (Planaria) locomotion as a functional endpoint. J Pharmacol Toxicol Methods 45:223-226.
41. Raffa RB, Stagliano GW, Umeda S. 2003. κ-Opioid withdrawal in planaria. Neurosci Lett 349:139-142.
42. Raffa RB, Baron DA, Tallarida RJ. 2006. Schild (apparent pA2) analysis of a κ-opioid antagonist in planaria. Eur J Pharmacol 540:200-201.
43. Raffa RB, Cavallo F, Capasso A. 2007. Flumazenil-sensitive dose-related physical dependence in planarians produced by two benzodiazepine and one non-benzodiazepine benzodiazepine-receptor agonists. Eur J Pharmacol 564:88-93.
44. Rawls SM, McGinty JF. 1997. L-trans-Pyrrolidine-2, 4-dicarboxylic acid-evoked striatal glutamate levels are attenuated by calcium reduction, tetrodotoxin, and glutamate receptor blockade. J Neurochem 68:1553-1563.
45. Rawls SM, Gomez T, Stagliano GW, Raffa RB. 2006a. Measurement of glutamate and aspartate in planaria. J Pharmacol Toxicol Methods 53:291-295.
46. Rawls SM, Rodriguez T, Baron DA, Raffa RB. 2006b. A nitric oxide synthase inhibitor (l-NAME) attenuates abstinence-induced withdrawal from both cocaine and a cannabinoid agonist (WIN 55212-2) in planaria. Brain Res 1099:82-87.
47. Rawls SM, Tallarida RJ, Zisk J. 2006c. Agmatine and a cannabinoid agonist, WIN 55212-2, interact to produce a hypothermic synergy. Eur J Pharmacol 553:89-98.
48. Rawls SM, Gomez T, Raffa RB. 2007a. An NMDA antagonist (LY 235959) attenuates abstinence-induced withdrawal of planarians following acute exposure to a cannabinoid agonist (WIN 55212-2). Pharmacol Biochem Behav 86:499-504.
49. Rawls SM, Gomez T, Raffa RB. 2008. A TRPM8/ TRPA1 channel agonist, icilin, atypically stimulates behavioral effects in planarians. Eur J Pharmacol 578:201-208.
50. Regunathan S, Feinstein DL, Raasch W, Reis DJ. 1995. Agmatine, the decarboxylated arginine is localized and synthesized in glial cells. Neuroreport 6:1897-1900.
51. Reis DJ, Regunathan S. 2000. Is agmatine a novel neurotransmitter in brain? Trends Pharmacol Sci 21:187-193.
52. Reynolds IJ. 1990. Arcaine uncovers dual interactions of polyamines with the N-methyl-D-aspartate receptor. J Pharmacol Exp Ther 255:1001-1007.
53. Sastre M, Regunathan S, Galea E, Reis DJ. 1996. Agmatinase activity in rat brain: A metabolic pathway for the degradation of agmatine. J Neurochem 67:1761-1765.
54. Sastre M, Regunathan S, Reis DJ. 1997. Uptake of agmatine into rat brain synaptosomes: Possible role of cation channels. J Neurochem 69:2421-2426.
55. Schwartz D, Peterson OW, Mendonca M, Satriano J, Lortie M, Blantz RC. 1997. Agmatine effects glomerular filtration via a nitric oxide synthase-dependent mechanism. Am J Physiol 272:F597-F601.
56. Segal DS, Kuczenski R. 2006. Human methamphetamine pharmacokinetics simulated in the rat: Single daily intravenous administration reveals elements of sensitization and tolerance. Neuropsychopharmacology 31:941-955.
57. Segal DS, Kuczenski R, O'Neil ML, Melega WP, Cho AK. 2005. Prolonged exposure of rats to intravenous methamphetamine: Behavioral and neurochemical characterization. Psychopharmacology (Berl) 180:501-512.
58. Su RB, Li J, Qin BY. 2003. A biphasic opioid function modulator: Agmatine. Acta Pharmacol Sin 24:631-636.
59. Su RB, Wei XL, Zheng JQ, Liu Y, Lu XQ, Li J. 2004. Anticonvulsive effect of agmatine in mice. Pharmacol Biochem Behav 77:345-349.
60. Tabor CW, Tabor H. 1984. Polyamines. Annu Rev Biochem 53:749-790.
61. Takamatsu Y, Yamamoto H, Ogai Y, Hagino Y, Markou A, Ikeda K. 2006. Fluoxetine as a potential pharmacotherapy for methamphetamine dependence: Studies in mice. Ann N Y Acad Sci 1074:295-302.
62. Umeda S, Stagliano GW, Raffa RB. 2004. Cocaine and κ-opioid withdrawal in planaria blocked by D-, but not L-, glucose. Brain Res 1018:181-185.
63. Umeda S, Stagliano GW, Borenstein MR, Raffa RB. 2005. A reverse-phase HPLC and fluorescence detection method for measurement of 5-hydroxytryptamine (serotonin) in planaria. J Pharmacol Toxicol Methods 51:73-76.
64. Uzbay IT, Yeşilyurt O, Celik T, Ergün H, Işimer A. 2000. Effects of agmatine on ethanol withdrawal syndrome in rats. Behav Brain Res 107:153-159.
65. Von Voigtlander PF, Lewis RA. 1982. U-50,488, a selective κ opioid agonist: Comparison to other reputed κ agonists. Prog Neuropsychopharmacol Biol Psychiatry 6:467-470.
66. Welsh JH, Moorhead M. 1959. Identification and assay of 5-hydroxytryptamine in molluscan tissues by fluorescence method. Science 129:1491-1492.
67. Welsh JH, Moorhead M. 1960. The quantitative distribution of 5-hydroxytryptamine in the invertebrates, especially in their nervous systems. J New Drugs 6:146-169.
68. Zomkowski AD, Santos AR, Rodrigues AL. 2005. Evidence for the involvement of the opioid system in the agmatine antidepressant-like effect in the forced swimming test. Neurosci Lett 381:279-283.